Topical Metformin: A Promising Alternative to Alleviate the Gastrointestinal Side Effects Associated with Oral Medication in Treatment of Type 2 Diabetes Mellitus

Sharayu P. Rathod*, Ashwini S. Sanap
Department of Pharmaceutics, MGV’s Pharmacy College, Panchavati, Nashik, Maharashtra, India.

*Corresponding author’s E-mail: sharayuprathod@gmail.com

Received: 11-11-2022; Revised: 25-12-2022; Accepted: 03-01-2023; Published on: 15-01-2023.

ABSTRACT

Diabetes mellitus (DM) is a chronic metabolic disorder which is characterized by persistent hyperglycemia. It can be due to an altered insulin secretion, resistance to insulin’s peripheral actions, or both. Metformin (dimethylbiguanide), is acknowledged as an essential frontline tool worldwide for the treatment of type 2 diabetes & is the highly prescribed oral hypoglycemic drug. It is the only biguanide derivative available in the market. It is the most affordable & effective medical option to deal with the disease. But there are prevailing & well known side-effects that arise with taking the medicine orally; amongst which the most prevalent are the gastrointestinal side-effects. The common GI side-effects associated with Metformin are diarrhea, constipation, anorexia, indigestion, dyspepsia, nausea, heartburn, vomiting, abdominal pain, bloating, retching, flatulence, etc. Innovations in technologies in development of transdermal drug delivery system for the treatment of diabetes will help in convenient and easy administration of the drug. Hence, in the present review article, we have made an attempt to explore the recent advances in the transdermal drug delivery system and the significant advantages of the novel topical/transdermal use of metformin over oral route of administration in order to lower down the gastrointestinal side-effects associated with the oral administration of the medication.

Keywords: Gastrointestinal side-effects, Metformin, oral, Transdermal, Topical, Type-2 Diabetes Mellitus.

INTRODUCTION

In 1957, Metformin was introduced in the USA after years of intensive research after the French physician Jean Sterne, first reported the use of metformin to treat diabetes in 1957. Metformin is widely used in the treatment of non-insulin-dependent diabetes mellitus and is highly effective in decreasing the risk of disease development. Metformin is a tried-and-tested medicine that has been used for decades to treat Type 2 Diabetes Mellitus, and is suggested by most experts as a first-line therapy. It is safe, affordable, effective, and well tolerated by most people. However, unwanted side-effects often come hand-in-hand with administering metformin orally. The most prevalent side-effects include the gastrointestinal side-effects that are encountered in at least one in three patients prescribed with Metformin, which in turn leads the patients to discontinue or suspend the medicinal treatment altogether (Fig.1). Fortunately, recent developments in topical/transdermal treatment options have offered patients a new way towards receiving the benefits of Metformin without facing the complications that arise after oral administration of the medicine in the treatment of Type 2 Diabetes Mellitus.

According to recent studies, the gastrointestinal system appears to be a key site of action for metformin hydrochloride. However, it is also the site of a prominent metformin drawback like intolerance, which often limits metformin dosing. For the short-term therapy of type 2 diabetes, the medication is prescribed orally in divided multiple doses of 300-500mg. Because of the drug’s short half-life, frequent administration is required, which leads to poor patient compliance (4-6hrs). As a consequence, an alternative non-invasive technique of drug administration is required. Transdermal delivery seems to be an appealing mode of administration for regulating Metformin hydrochloride blood levels for a prolonged period. Hence, due to the benefits of that transdermal systems offer over invasive injectable and oral dose forms, they have attracted increased attention and emerged as a viable hope in diabetes control over the last decade.

Figure 1: Gastrointestinal side-effects of Metformin (oral)
Transdermal Metformin Therapy (TMT) is a novel drug delivery method that provides the same be hoof of the medication that is obtained after taking the medicine orally, while eliminating or discarding the side-effects often seen with oral administration. Transdermal Metformin Therapy (TMT) is simply the incorporation of Metformin into a topically applicable base such as cream, ointment or gel that can be directly applied onto the skin. The Metformin gets pushed into the body through the skin and enters the systemic circulation/bloodstream. This therapy bypasses the Gastrointestinal tract altogether and avoids the first pass metabolism.

Mechanism of Action of Metformin

Metformin reduces hepatic glucose production & absorption. Treatment with Metformin decreases fasting plasma glucose by 25 to 30 %2. Metformin for its access to hepatocytes utilizes AMP Activated Protein Kinase (AMPK)3, resulting in reduced hepatic production of Glucose & decreasing glucose, utilization of glucose 3,4.

In liver & skeletal muscle the mitochondrial characteristic & AMPK pursuit have taken into consideration as budding mechanisms & has received a whole lot attention using which Metformin exerts its effects effectively. Metformin improves the lipid profile, in Polycystic Ovarian Syndrome, restores the characteristic of ovaries, & reduces infiltration of fat within the liver & lesser microvascular & macrovascular headaches associated to T2DM. Recently, in research Metformin has been observed as an introduction remedy for cancer, as gestational diabetes remedy & restores characteristic of ovaries & in pre-diabetic people for stopping T2DM 5.

Both through bringing down gluconeogenesis or through glycogenolysis7,8,9. In spite of the fact that in evaluating the rates of these metabolic forms there are confinements in these studies in terms of strategies utilized10. To a lesser extent, the glucose levels within the plasma are brought down by increasing peripheral glucose take-up by the fat tissues and skeletal muscles11. (FIG.2)

Gastrointestinal Side – Effects of Metformin:

The mechanism under metformin – induced Gl intolerance is not clear. However, there are different assumptions suggested, including stimulation of serotonin secretion in the intestines, changes in incretin, glucose metabolism and Bile salts malabsorption. Metformin structure was discovered to have some similarities with 5-hydroxytryptamine 5-HT3 selective agonists for receptors; transported by Serotonin Reuptake Transporter (SERT).Serotonin release (5-hydroxytryptamine (5-HT)) from the intestine leads to symptoms such as nausea, vomiting and diarrhea (FIG.3).

Figure 3: Serotonin release from intestine leads to GI problem

Duodenal biopsy study in subjects inexperienced with metformin it was discovered that metformin stimulates the release of serotonin from Enterochromaffin Cells; however, this effect is not mediated by 5HT3 receptors14,15.

Metformin absorption via SERT or Organic Cation Transporter (OCT1) results in reduced serotonin transport and GI side effects. The membrane of enterocytes expresses a number of solute service transporters which are concerned with the absorption of metformin from the intestinal lumen16. This contains organic cation transporter (OCT) 1, Plasma Membrane Monoamine Transporter (PMAT), carnitine/cation transporter 1, and OCT3 (FIG.5). The abated metformin transport by way of OCT1 increases the metformin aggregation in the entrails, developing in larger risk of GI prejudice (FIG.4). Metformin increases the bile acid pool in the colon, primarily via reducing ileum absorption. This alteration of enterohepatic bile salts has the potential to affect cholesterol homeostasis, glucose homeostasis, and enteroendocrine function (FIG.6). Changes in the microbiome and stool consistency could potentially contribute to metformin sensitivity13,14.
either by occlusion, by optimizing the formulation or by using physical methods. The most researched physical methods are iontophoresis, sonophoresis, electroporation and microneedles.

A] Physical Methods for Transdermal Drug Delivery

(a) Electrically Assisted Methods:

Iontophoresis

Iontophoresis is the most advanced painless and effective technology accelerating the transport of ionized and unionized moieties across the skin by means of electric current (usually, 500 microamperes cm²)\textsuperscript{16,17}. The drug delivery is based on the principle that like charges repel each other. Mechanism of iontophoresis includes diffusion, migration or electro-osmosis. Electro-osmosis is the mass flow of fluid that takes place in the same direction as the flow of counter-ions when a voltage difference is enforced. On implementation of electromotive force the drug repels and moves across the stratum corneum in the direction of the cathode placed elsewhere on the body\textsuperscript{18}. Iontophoresis offered rapid method of delivering water soluble and ionized medication into the skin; Reduces the chance of dose variation; Self-administration is possible; Bypasses hepatic first pass effect, higher patient compliance\textsuperscript{17}.

Sonophoresis

Sonophoresis/Ultrasound/Phonophoresis accelerates the movement of drug across skin using ultrasonic energy\textsuperscript{19}. Sonophoresis takes place when the ultrasound waves stimulate micro-vibrations in the pores and skin dermis and surges the kinetic power of molecules. When sound is discharged at a specific frequency, the sound waves disturb the lipid bilayer of Stratum corneum and enhances permeability\textsuperscript{19}. The sonophoresis offers several merits like avoids hepatic first pass effect, Reduces daily dosing, Substitute to oral administration when the route is unsuitable as in case of vomiting, diarrhea, etc., self-administration possible\textsuperscript{19}.

Electroporation

Also known as Electropemmeabilization is a remarkable increase in the electric conductivity and permeability of the plasma membrane of the cell resulting from an externally applied electric field. The definition of electroporation given by Tsong which is still widely accepted now is that electroporation is the transient loss of semi-permeability of cell membranes subject to the electric pulses, thus leading to “ion leakage, escape of metabolites, and increased uptake by cells of drugs, Molecular probes and DNA”\textsuperscript{20}. Short impulses of high voltage current are applied on the skin producing hydrophilic pores in the intercellular bilayers by temporary lipid re-alignment. Electroporation is effective with nearly all cell and species types\textsuperscript{21}. 

Recent Advancements in the Transdermal Drug Delivery Systems:

In the last few decades the advancement in technology has helped to improve the transdermal delivery of drug thus enabling the delivery of macromolecules through the skin. Different techniques can be applied in order to enhance the penetration of drug and bypass the stratum corneum
**Mechanical Method:**

**Microneedles**

Lately advances in bioengineering have brought about the emergence of numerous new "active" enhancement technologies designed to temporarily evade the stratum corneum barrier. Microstructured transdermal devices additionally referred to as microneedles includes hundreds of needles per array of microstructured projections covered with a drug or vaccine ranging in size from 100 microns to 2 mm; carried out to the pores and skin to offer intradermal shipping of lively agents, which in any other case might not cross the stratum corneum. The mechanism for delivery, however, isn’t always primarily based totally on diffusion. It’s primarily based totally on the transient mechanical disruption of the pores and skin and the position of the drug or vaccine in the epidermis where it is easier to get to the action site.

**Optimization of Formulation for Transdermal Drug Delivery**

**Nanocarriers**

Nanocarriers are categorized into colloidal structures with an average of less than 500 nanometres. Emerging Nanocarriers, including liposomes, nanoparticles (NPs), Nano-emulsion, and Micro-emulsion are the most studied for transdermal drug delivery. Lipid-based NPs, including liposomes, solid lipid nanoparticles, niosomes, carriers of nanostructured lipids and Nano-emulsions are widely used for transdermal drug delivery.

**Solid Lipid Nanoparticles (SLNs)**

Gasco & Muller in 1991 discovered Solid Lipid Nanoparticles. SLNs are usually spherical with size ranging between 50 to 1000nm. SLNs are made up of lipids physiologically dispersed in aqueous surfactant solution or water. SLNs were designed with the aim to over-power the demerits associated with liquid state of oil droplets. The lipid nature of SLNs increases their efficiency at trapping and deep penetration into the skin. The choice of surfactant and lipid mixture plays a vital role in lipid nanoparticle drug encapsulation. NPs systems based on lipids may have a thick layer on the surface of the skin with an occlusive effect thus improving the hydration of the skin. The implication of the surfactants present in this system may loosen or fluidise the layer cornea and may improve the permeation of loaded drug.

Advantages – Feasible for both hydrophilic and hydrophobic/lipophilic drugs, increases drug stability, enhanced biocompatibility etc.

**Nanostructured Lipid Carriers (NLCs)**

NLC, the second generation of SLNs consists of a binary blend of solid lipids and a spatially different fluid lipid as a hybrid carrier with average size between 10-500 nm. The NLC mixture consists of a long chain of liquid and lipids (oil) with a ratio of 99.9 to 0.1 and a short chain of solids and lipids with ratio 70:30. Solid lipid carrier systems that are available in nanometre such as solid lipid nanoparticles (SLN), was introduced as an alternative to liposome. SLN has multiple limitations. Incomplete ability to load medicines and expel medicines through storage, all these limitations can be minimized or removed by the new DDS solid lipids NLCs. New and modified type of NLC’s are available having a meticulous nanostructure. These meticulous nanostructures help to improve the stability of the formulations as well as enhance the bioavailability, drug loading etc. NLC’s additionally minimizes the extraordinary troubles which are related to the SLN for a number drugs, troubles like low payload, drug expulsion in the course of storage and SLN’s dispersions due to the excessive water content material in it. NLC is able to transport both lipophilic and hydrophilic drugs at the same time; NLC’s help improving stability of pharmaceuticals by facilitating control and targeted drug release.

**Liposomes**

Liposomes are closely related colloidal structures consisting of one or more lipid bilayer spheres holding water compartments. The purpose of any DDS is to modulate the pharmacokinetics and distribution of the drug in a useful way. Among the various systems of administration, liposome applications formulations and products are extremely wide-ranging. Due to its ability to carry wide range of drugs such as Anticancer, Antimalarial, Antifungal drugs, etc. Advantages – increases efficacy, stability, increased pharmacokinetic effects, facilitates transport of drugs across membranes.

**Niosomes**

Niosomes are monolayer or multilayer spheroidal structures made of surfactants and regarded as the counterpart of liposomes. They can incorporate both hydrophilic and lipophilic moieties. They improve the oral solubility and bioavailability of minimally soluble drugs and also improve skin permeability of drugs when applied by topical method. Niosome shows flexibility in their characteristic structure and can be designed depending upon the desired situation. They can be delivered to the site of action orally, parenterally as well as topically.

**Nanocrystals**

Drug nanocrystals are pure solid drug particles with an average diameter of less than 1000 nm. The term drug nanocrystals implies a crystal state of discrete particles, but depending on the method of production they may also be partially or completely amorphous. Drug nanocrystals are formed by reducing the particle size, resulting in an increase in the solubility of the drug. This technology is therefore being studied to increase the bioavailability of medicines that are not very soluble in water. Nanocrystals are ideal for administration on all routes, enhances solubility and oral bioavailability.

**Nanoparticles**

Nanoparticles are composed of a minimum of 100 atoms. Nanoparticle, is the combined name for the nanosphere...
and nanocapsules. Nanoparticles are recognized to be targeted drug administration because of its targeting nature. Nanoparticles are used to dispense DNA, medications, proteins. Due to its nature, size and optical property, it helps the nanoformulation to easily penetrate the physiological barrier and reach the target cell. It can be administered through various routes, it offers targeted delivery of drug, and it increases the resistance time of the drug.

Previous Studies on the Transdermal Drug Delivery of Metformin HCl:

<table>
<thead>
<tr>
<th>Name of author</th>
<th>Year of study</th>
<th>Study carried</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ali Nokhodchi, Jafar Akbari et.al</td>
<td>2018</td>
<td>Developed Topical gel of Solid Lipid Nanoparticle: A hopeful promise as a Dermal Delivery System.</td>
</tr>
<tr>
<td>Nitan Bharti Gupta et.al</td>
<td>2012</td>
<td>Formulated and Evaluated Metformin proniosomal gel for the treatment of Diabetes Mellitus.</td>
</tr>
<tr>
<td>Ryan F. Donnelly et.al</td>
<td>2018</td>
<td>Formulated and Characterized Hydrogel forming Microneedles for enhancing Transdermal delivery of Metformin.</td>
</tr>
</tbody>
</table>

**Topical solid lipid nanoparticle gel:**

Ali Nokhodchi, Jafar Akbari et.al (2018) performed formulation of Solid Lipid Nanoparticles loaded Topical gel of Metformin with the aim of enhancing dermal delivery of Metformin by using Ultrasonication method. It was observed that solid lipid nanoparticles are suitable carrier for skin delivery of metformin. It helped increase the skin delivery of higher concentrations of metformin to the deeper layers of the skin. The study suggested that Solid Lipid Nanoparticle loaded topical gel of Metformin can be a hopeful promise for Dermal Delivery.

**Proniosomal gel:**

Nitan Bharti Gupta et.al (2012) performed study on formulation and evaluation of Metformin Proniosomal Gel for Treatment of Diabetes Mellitus. Metformin hydrochloride was successfully integrated by coacervation phase separation method in proniosomal preparations which prolonged drug delivery. Surfactant used in the proniosomal gel formulation also helped enhance the penetration. Pronosomes gels were found to have high capture efficiency and also mediate controlled systemic transdermal delivery of metformin hydrochloride for the treatment of type 2 diabetes. Metformin hydrochloride could be prescribed in low-dose pronosome gels for transdermal administration. This improves bioavailability, protects recipients from high-dose damage.

**Hydrogel-forming microneedles (MN):**

Ryan F. Donnelly et.al (2018) formulated Hydrogel-forming Microneedles to amplify the transdermal delivery of Metformin Hydrochloride. Hydrogel-forming microneedle arrays (MN) were typically formed from the aqueous blends of poly (methylnvinylether/maleic acid) and poly (ethylene glycol) with the help of micromoulding process using silicone moulds that were prepared by laser engineering technology. It was found that Hydrogel-forming MN, which itself is drug-free, swells in the skin and diffuses the drug contained in the adhesive reservoir layer into the skin microcirculation for systemic absorption. The study demonstrated the ability of hydrogel-forming MNs to enhance transdermal delivery of a metformin hydrochloride. Hydrogel-forming MN may enable sustained transdermal delivery of metformin HCl, which can minimize gastrointestinal side effects and avoid fluctuations in small intestinal absorption associated with oral routes of administration. Hydrogel-forming microneedles have showcased the ability to enhance the transdermal delivery of many therapeutic substances with a wide range of physicochemical properties. This highlights the versatility of this MNs type and shows that hydrogel-forming MNs have considerable promise for commercial success. When introduced into the skin, hydrogel-forming MN comes into contact with interstitial fluid. MN swells to form a porous aqueous microduct through which the drug substance diffuses and reaches the microcirculation of the skin. The aqueous network produced by these MNs is suitable for Transdermal delivery of relatively water-soluble drugs such as metformin HCl. Thus Hydrogel-forming MNs are clearly a promising technology that could be used to enhance transdermal delivery of a metformin HCl.

**Transdermal Patch:**

Ravi Teja Allena et.al (2012) developed Transdermal Patches of Metformin Hydrochloride for Sustained...
release. Transdermal patch is an adhesive patch that is placed on the skin with the intent to deliver a sustained-released dose of medication through the skin to treat systemic illnesses. The first transdermal patch approved in the US by the FDA. Such system provides a variety of significant clinical advantageous over others like tablet and injections. Transdermal patch provides controlled release of the drug into the patient, and enables a steady blood-level profile, leading to reduced systemic side effects and, sometimes, improved efficacy over other dosage form. In addition, the dosage form of transdermal patches is user-friendly, convenient, painless, and offers multi-day dosing, it is generally accepted for delivery of metformin HCL to treat the type 2 diabetics.

Transdermal patch are type of drug delivery system which are designed to support the passage of metformin HCL from the upper surface of the skin into the systemic circulation. Permeability of the transdermal drug is primarily affected by the three factors-mobility of the drug within the vehicle, release of drug from the vehicle and permeation. The most tremendous advantage to patients will have a much easier treatment option in which a transdermal patch with predetermined release rate can be applied to the skin. A long-lasting drug release profile also ensures better glucose control and better glucose profile prediction. The prepared transdermal patch showed optimum drug content and sustained drug release. The study reported that application of transdermal patches containing Metformin hydrochloride achieved sustained drug delivery without gastric irritation.

CONCLUSION

Since diabetes mellitus is a chronic condition that requires long-term medication, innovation in treatment strategies would be appreciated. Transdermal medication in diabetes management are seen as a promising approach to achieving better clinical outcomes. A higher drug bioavailability may be achieved, and with this, diabetic sufferers will then have a lesser dosing frequency as compared to twice-every day dosing of traditional oral agents and 3 instances or maybe 4 instances every day of insulin injection. Compared to SC insulin injecting, transdermal delivery could help reduce stigma whereby patients must inject themselves with insulin. Overall, this area becomes an effort for researchers to explore and venture in as various transdermal approaches have shown very desirable advantages in improving the bioavailability of medicines, reducing the dosing frequency, and ease of administration resulting in better patient compliance. More dedicated research therefore needs to be done in order to alleviate the gastrointestinal side-effects that come from taking the medication orally.

REFERENCES


Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com